Oyster Point Pharmaceuticals
A clinical stage pharmaceutical company focused on the discovery development & commercialization .
Launch date
Employees
Market cap
AUD463m
Enterprise valuation
AUD503m (Public information from Jan 2023)
Share price
$11.17 OYST
San Francisco California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$22.0m | Series A | ||
$93.0m | Series B | ||
| N/A | N/A | IPO | |
* | N/A | $121m | Post IPO Equity |
* | $415m Valuation: $415m | Acquisition | |
| Total Funding | AUD178m | ||
Related Content
Recent News about Oyster Point Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.